Other Diseases

Fresenius Kabi introduced Bivalirudin for Injection Fresenius Kabi announced that it has introduced Bivalirudin for Injection in the United States, which is an anticoagulant, and a generic alternative to Angiomax. Fresenius Kabi’s Bivalirudin was approved by the U.S. Food and Drug Administration in October. The U.S. market for Bivalirudin for Injection is approximately $240 million. Fresenius Kabi’s Bivalirudin for Injection is available in single-dose vials, each containing 250 mg of Bivalirudin. Envigo Launches Hepatotoxicity Testing Envigo has launched a program of in vitro technologies aimed at helping to predict the likelihood of compounds causing Drug Induced Li...